(RTTNews) – AstraZeneca Plc (AZN. L, AZN) stated that the first participants had been dosed in a phase I trial of AZD7442 for the prevention and remedy of COVID-19 The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442 It will arrive with up to 48 healthy participants in the UK elderly from 18 to 55 years old.
AZD7442 is a mixture of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered through vanderbilt University Medical Center and authorized by AstraZeneca in June 2020, mAbs have been optimized through AstraZeneca. the moment begins in 2020.